Kevin Balthaser - 01 Mar 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Financial Officer
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
01 Mar 2024
Net transactions value
-$1,757
Form type
4
Filing time
05 Mar 2024, 17:02:09 UTC
Previous filing
05 Feb 2024
Next filing
04 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +1,100 +5.4% 21,525 01 Mar 2024 Direct F1
transaction ACRS Common Stock Tax liability $388 -313 -1.5% $1.24 21,212 01 Mar 2024 Direct F2
transaction ACRS Common Stock Options Exercise +2,375 +11% 23,587 01 Mar 2024 Direct F1
transaction ACRS Common Stock Tax liability $839 -677 -2.9% $1.24 22,910 01 Mar 2024 Direct F2
transaction ACRS Common Stock Options Exercise +1,500 +6.5% 24,410 02 Mar 2024 Direct F1
transaction ACRS Common Stock Tax liability $529 -427 -1.7% $1.24 23,983 02 Mar 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -1,100 -50% $0.000000 1,100 01 Mar 2024 Common Stock 1,100 Direct F1, F3
transaction ACRS Restricted Stock Units Options Exercise $0 -2,375 -33% $0.000000 4,750 01 Mar 2024 Common Stock 2,375 Direct F1, F4
transaction ACRS Restricted Stock Units Options Exercise $0 -1,500 -100% $0.000000* 0 02 Mar 2024 Common Stock 1,500 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
F4 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date.
F5 The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

Remarks:

Exhibit 24.1 - Power of Attorney